CCBIO-seminar 11. juni 2026 - Ricardo Coletta
Velkommen til CCBIOs seminarserie i vårsemesteret 2026! Foreleser er professor Ricardo Coletta, Universidade Estadual de Campinas (UNICAMP), Brasil. Åpent for alle i auditoriet i Armauer Hansen Hus. Påmelding er ikke nødvendig, bare møt opp. Velkommen!
Hovedinnhold
Foreleser: Professor Ricardo Coletta, Universidade Estadual de Campinas (UNICAMP), Brasil
Tittel: Biomarkers in Oral Cancer: From Discovery to Clinical Impact
Vert: Daniela Costea
Sted: Auditoriet i Armauer Hansens Hus
Når: 11. juni 2026 kl. 14.30–15.30
Påmelding er ikke nødvendig. Merk derimot at hvis du er student og trenger studiepoeng for oppmøte, må du ha meldt deg opp i Studentweb for dette emnet for gjeldende semester.
Abstract:
Ricardo D. Coletta has been Professor of Oral Pathology in the Department of Oral Diagnosis at UNICAMP School of Dentistry at Piracicaba since 2017 and currently serves as a Visiting Professor in the research group of prof Tuula Salo in the Department of Oral and Maxillofacial Diseases at the Faculty of Medicine, University of Helsinki. His research focuses on the cellular and molecular mechanisms underlying oral cancer tumorigenesis, with an emphasis on identifying biomarkers that may improve treatment strategies and prognostic assessment.
This presentation will examine the landscape of biomarker discovery in oral squamous cell carcinoma (OSCC), integrating histopathological, proteomic, and molecular approaches. I will highlight recent advances in histopathological biomarkers, including tumor budding, stromal activation, and other microenvironment‑driven prognostic indicators. The talk will also explore proteomic‑based biomarker identification, emphasizing how large‑scale protein profiling can uncover pathways associated with tumor aggressiveness, survival, and therapeutic vulnerability. Finally, I will discuss the development and characterization of cisplatin‑resistant OSCC cell lines, focusing on their epithelial-mesenchymal transition signature and its relevance for predicting treatment response and identifying resistance‑related biomarkers.